SCHEMBL8764931

SCHEMBL8764931

COCCCCN1C(=O)C=CC1=O

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 9/20 0.67
FAAH O00519 5/20 0.67
ALDH1A1 P00352 2/20 0.64
LMNA P02545 2/20 0.64
MAPT P10636 2/20 0.64
NPSR1 Q6W5P4 2/20 0.64
HSP90AA1 P07900 1/20 0.64
TLR9 Q9NR96 1/20 0.64
TP53 P04637 1/20 0.64
PKM P14618 1/20 0.64
HPGD P15428 1/20 0.64
XBP1 P17861 1/20 0.64
MAPK1 P28482 1/20 0.64
HTT P42858 1/20 0.64
RECQL P46063 1/20 0.64
RAB9A P51151 1/20 0.64
SMN1; SMN2 Q16637 1/20 0.64
GPR35 Q9HC97 1/20 0.64
GPR55 Q9Y2T6 1/20 0.64
PTGS1 P23219 7/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17192614 0.98 MGLL (0.68) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL14996147 0.98 MGLL (0.68) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL7093769 0.94 MGLL (0.62) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL24686928 0.89 MGLL (0.61) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL14134299 0.86 MGLL (0.62) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL18515649 0.86 MGLL (0.52) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL10147975 0.85 MGLL (0.57) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL409521 0.85 MGLL (0.64) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL10147978 0.83 MGLL (0.59) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL28532542 0.83 PTGS1 (0.46) MGLLFAAHALDH1A1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020217710-A1 COMPOUND, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT JNC株式会社 2020-10-29 WO disclosed
US-9446139-B2 Polymer-based compositions and conjugates of HIV entry inhibitors NEKTAR THERAPEUTICS (US) 2016-09-20 US disclosed
US-8895759-B2 Intermediates useful in the preparation of maleimide functionalized polymers NEKTAR THERAPEUTICS (US) 2014-11-25 US disclosed
US-20140128619-A1 Intermediates Useful in the Preparation of Maleimide Functionalized Polymers NEKTAR THERAPEUTICS (US) 2014-05-08 US disclosed
US-8586711-B2 Polymer-factor IX moiety conjugates NEKTAR THERAPEUTICS (US) 2013-11-19 US disclosed
US-8293869-B2 Polymer conjugates of GLP-1 NEKTAR THERAPEUTICS (US) 2012-10-23 US disclosed
US-8273339-B2 Polymer-based compositions and conjugates of antimicrobial agents NEKTAR THERAPEUTICS (US) 2012-09-25 US disclosed
US-20110171161-A1 POLYMER CONJUGATES OF PROTEGRIN PEPTIDES NEKTAR THERAPEUTICS (US) 2011-07-14 US disclosed
US-20100249033-A1 POLYMER FACTOR IX MOIETY CONJUGATES NEKTAR THERAPEUTICS (US) 2010-09-30 US disclosed
US-7790835-B2 Water soluble, non-peptidic polymer covalently attached to a Diels-Alder bicyclic or tricyclic imide ring; chemical intermediates NEKTAR THERAPEUTICS (US) 2010-09-07 US disclosed
US-7714114-B2 Conjugates of an EPO moiety and a polymer NEKTAR THERAPEUTICS (US) 2010-05-11 US disclosed
US-7579444-B2 Polymer-factor IX moiety conjugates NEKTAR THERAPEUTICS AL, CORPORATION (US) 2009-08-25 US disclosed
WO-2008074004-A2 HUMAN ANTIBODIES THAT BIND CD70 AND USES THEREOF MEDAREX, INC. (US) 2008-06-19 WO disclosed
US-20070092482-A1 Conjugates of a G-CSF moiety and a polymer NEKTAR THERAPEUTICS 2007-04-26 US disclosed
EP-0601974-B1 Positive photoresist with better properties OCG MICROELECTRONIC MATERIALS (US) 1997-05-28 EP disclosed
US-5558978-A Photoresist compositions containing copolymers having acid-labile groups and recurring units derived from either N-(hydroxymethyl)maleimide or N-(acetoxymethyl)maleimide or both OCG MICROELECTRONIC MATERIALS, INC. (US) 1996-09-24 US disclosed
EP-0659781-A2 Copolymers of maleimide, for photoresists OCG Microelectronic Materials Inc. (US) 1995-06-28 EP disclosed
US-5397680-A Light sensitive elements with maleimide monomers and styrene derivatives polymers CIBA-GEIGY AG (CH) 1995-03-14 US disclosed
US-5369200-A Positive photoresist having improved processing properties CIBA-GEIGY AG (CH) 1994-11-29 US disclosed
EP-0601974-A1 Positive photoresist with better properties OCG Microelectronic Materials Inc. (US) 1994-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140128619-A1 Intermediates Useful in the Preparation of Maleimide Functionalized Polymers DERA, MMAB, PAICS MGLL 3710/4885FAAH 4109/4885ALDH1A1 74/4885
US-20110171161-A1 POLYMER CONJUGATES OF PROTEGRIN PEPTIDES PSMG3, PSMB11, PSMC5 MGLL 3264/4885FAAH 3421/4885ALDH1A1 4840/4885
US-20100249033-A1 POLYMER FACTOR IX MOIETY CONJUGATES F9, F13A1, F8 MGLL 3516/4885FAAH 3292/4885ALDH1A1 3118/4885
US-20070092482-A1 Conjugates of a G-CSF moiety and a polymer CSF3R, GMFG, CSF1R MGLL 1573/4885FAAH 3126/4885ALDH1A1 3741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.